Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine

Oncology drug development historically has followed a path of sequential phase I, II, and III clinical trials using traditional trial designs, with the goal of achieving regulatory approval. These studies are often conducted with inclusion criteria that limit enrollment to a single tumor type or tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Donald C., Guinigundo, Andrew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190802/
https://www.ncbi.nlm.nih.gov/pubmed/37206904
http://dx.doi.org/10.6004/jadpro.2023.14.3.16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190802/
https://www.ncbi.nlm.nih.gov/pubmed/37206904
http://dx.doi.org/10.6004/jadpro.2023.14.3.16

Ejemplares similares